miRagen Therapeutics has signed a potential US$1 B research, development and commercialisation pact with France’s Les Laboratoires Servier for two of its preclinical-stage cardiovascular microRNA programmes, miR-208 and miR-15/195, plus an as yet unidentified target. Servier will gain global rights to the programmes, excluding the US and Japan where miRagen retains rights. miRagen will benefit from Servier’s expertise in cardiovascular drug development and will receive up to US$45 M in upfront, research support and near-term milestone payments over the next 3 years.